Search

everythinglearnresearchcommunity

for

Search:↓

Patients with metabolic syndrome had lower Gleason scores when diagnosed with prostate cancer.

Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

More prostate biopsies increase the chance of finding cancers that may not need treatment.

More biopsy cores and MRI before biopsy can improve prostate cancer detection.

Men with more advanced male pattern baldness have a higher risk of prostate cancer and more severe disease.

PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.

The main prostate diseases in dogs are benign growth, infections, and cancer, with various treatments ranging from drugs to surgery, but cancer treatments have limited success.

Male pattern baldness may predict prostate cancer risk.

Dutasteride reduces prostate cancer risk by 23% in high-risk men.

Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.

The guidelines aim to find treatable prostate cancer early while avoiding unnecessary tests and treatments.

PSA screening's effectiveness in reducing prostate cancer deaths can vary based on trial design and participant compliance.

The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.

Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.

Incidental prostate cancer was found in 4.89% of patients undergoing surgery for benign prostatic hyperplasia.

Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.

5α‐reductase isozymes are crucial for prostate development and health, and targeting them can help prevent and treat prostate issues.

Serum triglyceride levels are not linked to prostate cancer risk.

The research found that androgens help control blood flow in the rat prostate through a specific binding site.

Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.

Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

Finasteride can reduce prostate cancer risk but may delay diagnosis and cause sexual side effects.

Extracellular vesicles and androgen receptors may help identify prostate cancer resistance and reduce SARS-CoV-2 infection.

Men with early hair loss may have a higher risk of enlarged prostate and possibly prostate cancer due to shared hormonal factors.

Men who start balding at age 20 may have a higher chance of getting aggressive prostate cancer.

Age, race, family history, and certain genetic factors increase prostate cancer risk.

Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.